Roche stakes $22B bet on Chinese ADCs
Roche is making a big bet on Chinese-developed antibody-drug conjugates (ADCs), signing a deal worth up to $22 billion (US$15.5 billion) with Hansoh Pharmaceuticals.
To see the whole article, log in or create an account.